FDA May Support HIV Prevention Drug for the First Time

A Gilead Sciences HIV drug may be the first to gain the support of the U.S Food and Drug Administration (FDA). On Tuesday the FDA seemed to take an interest in the HIV prevention drug, which may prevent healthy users of the medication from getting the virus from their partners.

The HIV prevention drug, called Truvada, is hoping to get FDA approval to be marketed to consumers who have high chances of contracting the virus. It is currently a very popular drug on the market and is used along with other drugs to help treat HIV. By Thursday, the FDA is hoping to reveal their answer on whether or not they will recommend the drug for HIV prevention. The FDA has already claimed that those who use Truvada along with other preventive tactics “may be spared infection with a serious and life threatening illness.”

The drug would be marketed mainly for gay or bisexual men along with heterosexual couples in which one partner is already infected with the virus since they are the consumers who are expected to be at high risk for getting HIV. Although the drug does show hope for future development of a drug that can promise the prevention of HIV for all users, the FDA wanted to remind consumers that attempts at producing a vaccine “to prevent against HIV infection have thus far been unsuccessful.”

 

Subscribe To The ABS Newsletter — Get our stories in your inbox.

Independent journalism still matters.

We hope this story was worth your time. For over 14 years, Atlanta Black Star has stayed Black-owned and independently run. We didn't get here by waiting on ad budgets that were never built to prioritize us. Our readers did that.

Corporate support for Black media has always been thin. Outlets like ours get roughly 1% of the $170 billion spent on U.S. advertising each year, and that margin is shrinking further as advertisers walk back the DEI-linked commitments they made in 2020. That's the backdrop. It's not why we're asking.

The wider picture isn't any steadier. Newspaper ad revenue has fallen more than 80% since 2005, and local newsrooms are closing at a rate of roughly two a week nationwide. When outlets go under, it's rarely the ones built to center a Black perspective from the ground up that get to stick around.

We know a request for support isn't why you came here. But without readers choosing to fund this work directly, the depth of reporting we can do at home and abroad shrinks along with everyone else's. If you're not in a position to give, that doesn't change how much we value you as a reader.

If you are able to, a recurring contribution does more for us than a single one-time gift, because it lets us plan the next investigation instead of just the next invoice. It takes about 30 seconds, no long form, no account. Thank you for continuing to support independent journalism and freedom of the press.

Latest from Atlanta Black Star

Back to top